ZINC SULFATE FOLIC ACID TABLETS / FOLINZ

     

COMPOSITION

Each sugar – coated tablet contains:

Zinc sulfate monohydrate USP - 55mg

Folic Acid                                BP – 5 mg

Colours ponceau 4R & titanium Dioxide BP

DESCRIPTION:

folinz is a single tablet containing Folic Acid and Zinc, which makes it an important vitamin nutritional supplement, Zinc is a vital trace element plying multiple role in the human body. Zinc boosts up immunity, improves resistance in disease conditions. Zinc also plays a major role in many metabolic activities in the body. Folic acid helps to prevent first occurrence of spina bifida and other neural tube defects in the newborn.

PHARMACOLOGY:

PHARMACOKINETICS:

Folic acid is absorbed mainly from the proximal part of the small intestine. Folate polyglutamates are considered to be de – conjugated to monoglutamates during absorption. Folic acid rapidly appears in the blood, where it is extensively bound to plasma proteins. The amounts of Folic acid absorbed from normal diets are rapidly distributed in body tissues and about 4 to 5 micrograms is excreted in the urine daily. When larger amounts are absorbed, a high proportion is metabolised in the liver to other active forms of folate and a proportion is stored as reduced and methylated folate. Larger amounts of folate are rapidly excreted in the urine. Zinc and its salts are poorly absorbed from  GIT (in duodenum and ileum) and only small portion of dietary Zinc is absorbed and is widely distributed throughout the body and excreted mainly in the feces and only traces are found in the urine since kidney has little role in regulating body Zinc content. Endogenous Zinc be reabsorbed in ileum and colon creating enterohepatic circulation of Zinc. After absorption Zinc is bound in the intestines to protein metallo thionein. Zinc is primarily stored in RBCs, WBCs, muscle, bone, Skin, Kidneys, Liver, pancreas,  retina, prostate etc, The extent of binding is 0%  to plasma albumin, 30-40%  to alpha 2 macroglobulins or transferrin and 1% to amino acids like histidine and cysteinc. Peak peas ma concentration occurs in approximately 2 hours and elimination is primarily fecal constituting 90%  and small amounts in urine and sweat.

PHARMACODYNAMICS:

 The daily folate requirement rises steeply during the final trimester of pregnancy, and evidence of maternal depletion may be found. To ensure normal tissue folate levels in the mother after delivery a daily supplement of about 300 micrograms is required during the second and third trimester of pregnancy. This does not obscure the blood picture of addisonian pernicious anaemia.

Zinc is an essential element of nutrition and traces are present is wide range of foods.

Zinc is an essential element of nutrition and traces are present is wide range of foods Zinc salts (usually Zinc sulfate) are used as supplements to correct Zinc deticiency and have been used to treat large number of conditions because of an associated reduction in the concentration of Zinc in the body

INDICATIONS:

folinz is recommended as a Vitamin & Zinc supplement and are in especially beneficial in following condition:

                     For the prophylaxis and treatment of nutritional megaloblastic anaemias associated with folic acid deficiency, as in the anaemias of pregnancy, pellagra, sprue and that following gastrectomy and in pernicious anaemia.

                   Vital role in various intercellular reactions likely conversion of Serine, glycine,  Synthesis of Purines, DNA and RNA.

                  Coenzyme  for metabolic processes.

                  Used in the treatment of folate deficiency.

                  Boosting up  Immunities.

                  Proper  growth of foetus.

                   For the periconceptual  supplementation of Folic Acid to help prevent first occurrence of spina bifida and other neural tube defects in the new born.

                 Prevent foetus malformations due to Zinc deficiency in pregnancy.

CONTRAINDICATIONS:

 folinz in contraindicated in patients with known hypersensitivity to any of the ingedients  in the formulation. It should never be used in the therapy of patients with vitamin B12 deficiency of any cause unless here is associated folate deficiency. Proper haematological diagnosis is essential.

WARNING:

Concurrent administration of Zinc might diminish the effect of penicillamine. Folic should never be given alone in the treatment of Addison’ s pernicous anaemia and other vitamin B 12 deficiency states because it may precipitate the onset of subacute combined degeneration of the spinal cord.

SIDE EFFECTS:

folinz is generally well tolerated in recommended doses. Rare side effects may include gastro – intestinal disturbances, nausea, vomiting and diarrhoea. Accumulation of Zinc may occur in cases of renal failure.

PREGNANCY AND LACTATION:

 there is published evidence that folic acid is beneficial in the prevention of neural tube defects.

INTERACTIONS:

folic acid occasionally reduces plasma levels of anticonvulsants. Particularly  phenytoin.

DOSAGE:

 As directed by the Physician.

OVERDOSAGE:

No cases of acute overdosage of Folic acid appear to have been reported, but even extremely hihg doses are unlikely to cause harm to patients.

PRESENTATION:

Folinz tablets are available in blister strip of 30 tablets in an attractive carton.

STORAGE:

 Store below 25 C in a dry a place. Protect from light Keep out of reach of children.

ISSORBIDE DINITRATE TABLETS BP 10 mg

Suitabaly formulated for oral & sublingual use

For the use only of a Medical practitioner or a hospital or laboratory.

 DESCRIPTION OF PRODUCT:

White circular uncoated tablets having breaking marking on one side of the tablet.

COMPOTION:

Each uncoated tablet contains isosorbide dinitrate 10 mg as diuted isosorbide dinitrate Bp

THERAPEUTIC:

Antianginal

ACTION:

Compatible with beta blockers and calcium ion antagonist

INDICATIONS:

Isosorbide dinitrate is indicated for the treatment and prevention of angina pectoris, isosorbide dinitrate mat be used prophylactically to decrese frequeny severity of anginal attacks.

CONTRAINDICATIONS:

Isosorbide dinitrate is contraindicate in patient who have shown purported hypersensitivity or idiosyncrasy to it or other nitra or nitrites.

ADVERSE REACTIONS:

Adverse reaction, particulary headache and hypotension, are dose related headache is the most common adverse reaction and may be severe and persistent, cutaneous vasodiliation with flushing may occur. Transient episodes of dizziness and weakness, as well as other signs of cerebral ischemia associated with postural hypotension, may occasionally develop. An occasional individual will exhibit marked sensitivity to the hypotensive efffect of nitrate. Drug rash and or extoliative dermatitis may occassionally occur. Nausea and vomiting appear to be uncommon.

DRUG INTEGRATION:

Alcohol may enhance any marked sensitivity to the hypertensive effect of nitrates. Isosorbide dinitrate acts on vascular smooth muscles. Therefore, any other agents that depends on vascular smooth muscle as the final common path can be and expected to have decreased effect depending on the agent.

DOSAGE:

½  to 1 tablet 4 times a day to be taken orally. Sublingual use. For immedaate action ½ to tablet to be taken sublingually.

OVERDOSAGE:

Sign any symptoms:

These include the fallowing a prompt fall in blood pressure,persistent and throbbing headach, vertigo, visual, distubances, flushed and perspiring skin (later becoming cold and cyanotic) nausea and vomiting (possibly with colic and even bloady diarrhoea), syncope, ( especially in upright position), methemolobinemia with cyanosis and anoxia, initial hyperpnea, dyspea and slow breathing, slow pulse ( discrotic and intermittent), heart block increased intracranial pressure with cerebral sympotoms of confusion and moderate fever, paralysis and coma follwed by clonic convulsions and possibly death due to circulatory collapse.

TREATMENT OF OVERDOSAGE:

Prompt removal of the ingested material by gastric lavage is reasonable. Keep the patient recumbent in a shock position and comfortably warm. Passive movements of the extermiies may aid venos retun. Administer oxygen and artificial respiration if necessary. If methemologbinemia is present administer methylene blue (1% solution), 1 to 2 mg. intravenously.

WARNING:

Epinephrine is ineffective in reversing the severe hypoteensive events associated with overdose. It and related compounds are contraindicated in this situation.

PRESENTATION : Pack of 1000 tablets.

SHELFLIFE : 36months.

STRAGE : store tightly closed in cool, dry place. (temperature not exceeding 25^oc)

GLYCHEK

GLICLAZIDE TABLETS BP

Glychek contains gliclazide, an oral hypoglycemic agent belonging to the sunfonylurea group whith is used widely for the treatment of type-2 diabetes mellitus.






COMPOSITION  :

GLYCHEK 40                                           GLYCHEK 80
Each uncoated tablet contains :                    Each uncoated tablet contains :  
Gliclazide    BP    40mg                              Gliclazide    BP    80mg
                                                                  Colour    :   ponceau     4R

DESCRIPTION :

Glicazide  acts the chemical name [1-(3-azabicyclo-[3,3,0]-oct-3-yl)-3-ptolylsulfonylurea. It has the chemicals formula  C15 H21 N3 O3 S and a molecular weght of 323.4.

PHARMACOLOGY :

gliclazide acts chiefky by stimulating the release of insulin from the B cell of the pancreas. in patients with type-2 diabete, it improves the defective insulin secretion and thus ensures glycaemic control. it also helps to decrease the peripheral insulin resistance to some extent. There is evidence that Cliclazide may help to improve the defective haemobiological activity in patients with  type-2 diabetes as seen by a decrease in platelet hyperadhesiveness and hyperaggregation, an increase in fibrinolytic activity and decrease in levels of free radicals.

PHARMACOKINETICS :

Gliclazide is really absorbed from the gastrointestinal tract. After oral administration the peak plasma  concentrations are achieved in about 2-8  hours. Glclazide is extensively bound to plasma proteins, the plasma protein binding being 92%. Gliclazide is xtensively metabolize in the liver, but the metabolites have no hypoglycemic activity. The metabolites and a small amount of the unchanged drug are excreted in the urine. The half-life of gliclazied is about 10-12 hours.

INDICATIONS :

Glychek 40 / 80 is indicated for the treament of type -2 diabetes mellitus in association with dietary measures and with physical exercise, when these measures alone are not sufficient to normalize the bolld glucose levels.

DOSAGE & ADMINISTRATION :

The usual initial dose of gliclazide is 40-80 mg daily, gradually increased if necessary to 320 mg daily. The doses may be given once daily or in 2 divided doses. Doses more than 160 mg daily should be given in 2 divided doses. The doses are administered half an hour before meals.

CONTRAINDICATIONS :

Glychek 40 / 80 is contraindicated in the following situations :
•    Type -1 diabetes mellitus
•    Hypersensitivity to sunfonylureas
•    Severe hepatic ans renal failure
•    Pregnancy and location
•    Patients with ketoacidosis
•    Patients undergoing surgery, after severe trauma or during severe infections.

DRUG INTERACITONS :

An increased hypoglycemic effect can occur on co-administration of sunfonylureas, including gliclazide, with the following drugs :
Salicylates, sulfonamides, alcohol, betablockers, azole antifungals like fluconazole, ketoconazole and miconazole, ACE inhibitors, MAO inhibitors, tricyclic anti-depressants, chloramphenicol, tetracyclines, thyroid hormones, cimetidine, ranitidine, clofibrate, allopurinol and oral anti coagulants. Care should be taken when gliclazide is administered with there drugs. A diminished hypoglycemic effect, possibly requiring an increase in gliclazide dose may occur with drugs like danazol, chlorpomazine, glucocorticoids, oral contracepives, rifamycins, thiazide diuretics and epinephrine.

USE IN SPECIAL POPULATION :

•    Pregnancy : Gliclazide is contraindicated in pregnancy.

•    Nursing Mother :  Gliclazide is contraindicated in a mother who is breast feeding her baby.
•    Pediatric use : As most patients in paediatric segment with diabetes mellitus have type-1 diabetes, Gliclazide is not indicated in such patients.
•    Geriatric  use : As elderly individuals are prone to some degree of renal failure, Gliclazide should be used with caution.
•    Use in Helpatic & Renal Impairment :  gliclazide should be used with caution in patientd with mild to moderate hepatic or renal impairments and should be avoided in patients with severe hapatic and renal impairments.

ADVERSE REACTIONS :  

The following adverse reactions may occur with sulfonylureas, including gliclazide: hypoglycemia, gastrointestinal  distubances like nausea, vomiting, anoreia, diarrhoea  and a metallic taste, dermatological side efffects like skin rashes, pruitus and photosensitivity have been reported. Rarely hypersensitivity reactions like raised liver enzymes and cholestatic jaundice, leukopenia, thrombocytopenia, aplastic anaemia, erythema multiforme or exfoliative dermatitis may occur.

WARNINGS & PRECAUTIONS :

All sulfonylureas including gliclazide, can cause episodes of hypoglycemia. Hypoglycemia may present with sweating, intense hunger, trembing , pallor, visual to disturbances, feeling of malasia and abnormal beheviour. If untreated it can lead to drowsiness, convulsions or coma, hypoglycemic coma can be fatal. Hance all patients given sulfonylureas must be taught to recognisse the symptoms of hypoglycemia and if it occurs be told to take either sugar or sugar containing food immedately and inform he doctor. Hypoglycemia can occur becouse of irrigular meal times, missed meals, chenges in dite, prolonged or strenous execise, by intale of alcohol or other hypoglycemic drugs. The patient should be warrned about the dangers of hypoglycemia whilst driving or  operating machinery. Patients who develop frequent episodes of hypoglycemia should not drive or operate machinery.

NIFEDPINE TABALETS

RETARD 1 mg

COMPOSITION :  Each sustained release film coated tablet         containns:
                                  Nifedipine S.S.P 10g

DESCRIPTION :  

 Calcium Antagonist, Cardiovascular therapeutic agent ( Antihypetensive & Antianginal)

PHARMACOLOGY :

Absorption :

Absorption is nearly complete from the jejunum after oral administration. Biovailability is however variable depending on first pass hepatic metabolism and ranges from 43 to 77% food increase the biovalibility of sustained release nifedipine tablet, tmax is attained at 6.0 hours. Nifedipine is highly bound to plasma proteins (92 to 98%) in particular albumin.

ELIMINATION :

The eliminate half-life of sustained release nifedpine is 10.5 hours. No accumulation of unchaned active substance is to be expected in the case of long term medication. Nifedpine is almost totally metabolized and only traces thereof are found in unchanged form of inactive metabolites and the rest in excreted in the faeces.

CLINICAL SITUATION WITH POSSIBLY CHANGED KINETICS :

In the case of renal insufficiency the kinetics are not affected although the hypotensive effect is enchanced. Doses of nifedipine must be reduced in liver cirrhosis.

MECHANISM OF ACTION :

Nifedipine inhibits the influx of calcium into  the heart muscle cells, the smooth muscle cell of the coronary arteries and the perpheral  arterioles (resistance vessels) nifedipine brings about an improvement in the oxygen supply to the heart muscle with simultaneous reduction of oxygen requirements, thereby exerting an antianginal effect. Normalization of eveated blood pressure is brough about by a reduction in peripheral resistance though the dilatation of the arterioles.

USUAL DOSAGE :

1 tablet of nicardia retard twice daily.

CONTRAINDICATIONS :

Nicardia retard to be avoide during pregnancy. No data are available regarding use in lacation. Nicardia retard should not be used in severe hypotension with danger of collapse.

SIDE EFFECTS :

The most common adverse effects of nifedipine therapy are headache flushing, dizziness, gastrointestinal symptoms and lower leg oedema, sweelling or fluid retention.
The main vasodilator related adverse of nifedipine is headache – flushing and dizziness have reported to necessitate treatment withdrawal in 2 to 6% of patients.

FENADIN

DESCRIPTION :

Fenadin 60    : Each tablet contains fexofenadine hydrochloride 60mg
Fenadin 120 : Each tablet contains fexofenadine hydrochloride 120mg
Fenadin 180 : Each tablet contains fexofenadine hydrochloride 180mg
Fenadin 50ml suspension : Each 5ml suspension contains fexofenadine hydrochloride 30mg

INDICATIONS & USAGE :

Seasonal Allegic Rhinitis
Fenadin is also indicated for the treatment of uncomplicated skin manifestations of chronic idiopathic urticana in adults and children 6 month and older.

DOSAGE AND ADMINISTRATION :
Seasonal Allergic Rhinitis

Adults and children 12 years and older :  The recommended does of fenadin  is 60mg twice daily, or 120mg or 180mg once daily. A dose of 60mg once daily is recommended as the starting dose in patients with decreased renal function.
Children 6 to 11 years : The recommended does of fenadin  is 30mg twice daily,  A does of 30mg once daily is recommended as the starting dose in pediatric patients with deresed renal function.
Chronic and children 12 years and older :
Adults and children 12 years and older :  The recommended does of fenadin is 60mg twice daily, A dose of 60mg once daily is recommended as the starting dose in patients with decreased renal function.
Children 6 to 11 years : The recommended does of fenadin is 30mg twice daily,  A does of 30mg once daily is recommended as the starting dose in pediatric patients with deresed renal function.
Fenadin  oral suspension
Seasonal Allergic rhinitis
Children 2 to 11 years : The recommended dose of fenadin oral suspension is 30mg twice daily. A dose of 30mg (5ml) once daily is recommended as the starting dose in pediatric with decreased renal function.

Shake the bottle well, before each use.

Chronic idiopathic urticaria
Children 6 months to 11 years: The recommended dose of fenadin  oral suspension is 30mg (5ml) twice daily for patients (5ml) twice for patients 2 to 11 years of age and 15mg (2.5ml) twice daily for patients 6 month to less than 2 years of age. For pediatric patient with decreased renal function, the recommended stating doses of fenadin oral suspension are 30mg (5ml) once daily for patients 2 to 1 years of age and 15mg (2.5ml) once daily for patients 6 months to less than 2 years of age.

Age group                                   Fenadin Tablet                            Fenadin Suspension

Adults and children ≥ 12                                                       
years                                            120mg once d
                                                             Or
                                                    180mg once daily +                                 N/A           
                                                             Or
                                                    60mg twice daily*  


Children                                       30mg twice daily*                          30mg(1tp) twice daily*               
6 to 11 years                                        N/A                                        30mg (1ts) twice daily*
2 to 5 years                                          N/A                                        15mg (1/2ts) twice daily*
6 month to less than 2 years                                                                 
                                                                        

                                                                                                
•    Starting dose in patients with decreased renal function should be the recommended dose indicated above but administered once daily.
+ dose not for use in patients with decreased renal function.
¥ Indicated for chronic idiopathic urticaria only.

SIDE EFFECTS:

The incidence of adverse events, including drowsiness, is not dose related and is similar across subgroup defined by age, gender and race. The other side effects are viral like infection (cold, flu), nausea, dysmenorrheal, fatigue, headache and throat irritation.

DRUG INTERACTION:

Fenadin should not be taken closely in time with aluminum containing antacid, erythromycin or ketoconazole co-administration may enhance fexofenadine absorption.

CONTRAINDICATION:

Fexofenadine hydrochloride is contraindicated in patients with known hypersensitivity to any of its ingredients.

PREGNANCY:

Ther e are no adequate and well-controlled studies in pregnant women. Fenadin should be used during pregnancy only if the potential benefit justifile the potent ial risk to the fetus.

NURSING MOTHERS:

No adverde effects have been in breast feeding infants whose mother were receiving fexofenadine hydrochloride and THE AMERICAN ACADAMY OF PEDIATRICS considers that it is therefore usually compatible with breast feeding.

PEDIATRIC USE:
Safety and effectiveness of fexofenadine hydrochloride in pediatric patient can be used up to the age of 6 month.

STORAGE:
Store in cool and dry place. Away from light.

ENALAPRIL MALEATE TABLETS

THERAPEUTIC CATEGOGY

ACE inhibitor for the treatment of hypertension

Composition

1 Each uncoated tablet contains
Enalapril Maleate   USP   5/10mg

MECHANISM OF ACTION:

Following oral administration, Enalapril Maleate is rapidly absorbed and hydrolysed to Enalapriat, a highly specific , long-acting, non-sulphydryl ACE (angiotensin-coverting enzyme) inhibitor. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin to the vasoconstrictor substance, angiotensin ll. Angiotensin ii also stimulates aldosterone secretion by the adrenal cortex. Inhibition of ACE results in decreased plasma angiotensin ii. Which leads to decreased vasopressor activity and aldosterone secretion, thus exerting antihypertensive action.

INDICATIONS:

All grades of essential hypertension and renovascular hypertension (exept in artery stenosis)
Hypertension complicated be diabetes mellitus, gout, asthma etc. As adjunctive therapy in comgestive cardiac failure with digitalis and/or diuretics, asmpomatic left ventricular dysfunction.

SIDE EFFECTS:

Mild headache, dizziness, gastro-intestinal upsets and angiodema are noted in few patients. Cough can be a trouble some side effect occasionally.

SPECIAL PRECAUTIONS:

In patients with severe congestive cardiac failure, treatment with ACE inhibitors  may lead to oligouria and acute renal failure. Angioedema has  been reported in patients treated with ACE inhibitors  including enalapril maleate. Pretreatment assessment of renal function is a must in renal faipure (less than 30ml/min) the dose of enalapril maleate should be reduced. It should be used with caution in patient’s with renal insufficiency. In hypertensive patients receving enalapril hypertension is more likely to occur if the patient has been volume depeted (e.g by diuretic  therapy, dietary salt restriction dialysis, diarrhoea or vomiting) similar consideration may apply to patients with ischaemic heart or cerebrovascula diesase in whom an excessive fall in blood pressure could result in a myocardial infarction. Enalapril should not be used in patients with aortic stenosis or outflow obstruction. Other antihypertensive agents may increase the antihypertensive efficacy. Enalapril is exxcreted in human milk. Caution should be exercised if it  is given to breast feeding mothers. 

CONTRAINDICATIONS:

Hypersensitivity to ACE inhibitors,pregnancy,children. Having a history of angioedema due to previous treatment ACE inhibitors.

DOSAGE AND ADMINISTRATION:

The recommenede initial dose in patients not on diuretics is 5 mg once a day. The usual dailly dose is 2.5 mg to 40 mg per day in a single dose or in two divided doses. The maximum daily dose is 40 g.

1)- Essential and renovascular hypertension:
Treatment should be initiated with 5 mg once a day. Dosage should be adjusted according to blood pressure response. Maintenace dose is 10-20 mg giving once daily. In severe hyperetnsion , the dosage may be increased to  maximum of 40 mg once daily. Where cocomitant therapy is a diuretic, the recommended initial dose is 2.5 mg.

2)- Heart failure/ symptomatic left ventricular dysfunction:
Initial dose is 2.5 mg once daily. The dose should be titrated gradually to the usual maintenace dose of 20 mg given as a single dose or two divided doses. Accoding to the tolerability of the patient.

3)- dosage adujustment in patients with heart failure and renal impairment or hyponatremia.
Dosage adujustment in patients with heart faifure and renal impairment or hyponatremia.
Therapy should be initiated at 2.5 mg daily under close medical supervision. The dose may be increased to 2.5 mg twice daily than 5 mg twice daily and higher ad needed. The maximum daily dose is 40 mg.

STORAGE:
Store at a temperature not exceeding 30o c in a dry place.

WORMIN 500

Wormin contains mebendazole. It is hightly effective and safe anthelmintic. It is useful in a wide range of single and mixed worm infestations. It is methyl (5- benzoylbenzimidazole -2- ylcarbamate.)

COMPOSITION:

Each tablet of wormin 500 contains.
Mebendazole U.S.P                       500mg

MODE OF ACTION:

Wormin exerts a local  action on the worms in the gastro-intestinal tract. It inhibits the glucose uptake of worms irreversibly resulting in parasite immobilization and death, worm clearance from the gastro-intestinal tract may occur up to 3 days after treatment. Wormin also inhibits the development of ova and larval froms.
Wormin is poorly absorbed from the gastro-intestinal from of decarboxylated metabolite. This poor absorption contributes to almost compelet lack of side effects with mebendazole.

INDICATION:

Wormin is effective agasinst large number of worms. Being broad spectrum in nature it is recommeded in single as well as mixed infestation. It is useful in the treatment of follwing worm infestation.
Ascaris lumbricoides        (round worm)
Ancylostoma duodenale     (old world hook worm)
Necator americanus         (new world hook worm)
Enterobius vemicularis         (thred worm or pin worm)
Trichuris trichiura        (whip worm)
Wormin has also been found to be effective in following worm infestations.
Taenia saginata            (beef tape worm)
Taenia solium            (pork tape worm)
Capillarie phillippinensis
Trichostrongylus
Trichinosis (hydatid cyst)
Echinococcus granulolsus
Strongyloides stercoralis


DOSAGE & ADMINISTATION:

Wormin is given orally in a single no special preparation like fasting or purging is required.
If the patient is not cured in 3 week after treatment a second course of wormin may be given. In hydatid cyst medical therapy with high dose mebendazole (40mg/kg/day) has been used successfully.

CONTRAINDICATIONS:

Pregnancy and hypersensitivity to mebendazole.

PRECAUTION:

The drug has been extensively studied in children under one year, therfore in the treatment of children below one year the benefits should be weighed against possible hazards.

ADVERSE REACTIONS:

WORMIN is virtually free from side effects. Transient abdominal pain and diarrhoea have beeen reported only rarely in cases of massive infestation of worms,. As a result of poor absorption mebendazole does not cause systemic toxicity in clinical use.

STOREGE:

TABLETS:

 TEMPERRATURE BETWEEEN 15 0C & 25OC

CAPTOPRIL TABLETS

CATEGORY:

ANTI HYPERTENSIVE

COMPOSITIONS:

Dosage form                                               STRENGTH
Tablets containing captopril USP                12.5 mg / 25 mg / 50 mg pre tablet
(un-coated / film-coated / sugar-coated)

INDICATIONS:
Severe / resistant hypertension, congestive heart failure, hypertension associated with diabetes.

CONTRA INDICATIONS:

Aortic stenosis, renal impairment, pregnancy, taste disturbance, gastric irritation, rash, pruritus, aphthous mouth ulcers, neutropenia, agranulocytosis proteinuria, nephritic syndrome, hypotension, angioedema, tachycardia, jaundice.

PRECAUTIONS:

In patients on diuretics, withdraw diuretics & correct sodium depletion if any by increasing sodium intake before starting captopril therapy. Reduced doses in renal impaired patients. Pregnancy & lactation, Anaesthesia in CCF, diuretics & digitalis must be given cancurrently, where appropriate.

DOSE:

Adult:  12.5 mg twice a day by month in the treatment of hypertension. Maintenance dose 25 mg to 50 mg twice daily should not exceed 50 mg three times a day.
Children:  1-6 mg/kg body weight in divided doses or as directed by the physician.

STORAGE:

Store in cool, dry place, protected from light at a temperature
Less than 30oc & relative humidity less than 65%
Keep out of reach of children